Results 41 to 50 of about 9,786 (244)

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

Experimental Hematology & Oncology, 2020
Background Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging.
Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi, Giovan Battista Ruffo   +8 more
doaj   +1 more source

Advances in iron chelation therapy: transitioning to a new oral formulation

Drugs in Context, 2017
Iron overload is a concern for patients who require repeated red-blood-cell transfusions due to conditions such as sickle cell disease, thalassemia, or myelodysplastic syndromes.
Nirmish R Shah
doaj   +1 more source

Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso

Revista Alergia México, 2023
Antecedentes: Deferasirox es un quelante de hierro activo, indicado en el tratamiento de pacientes con hemocromatosis; sin embargo, se ha informado que el 28% de los casos puede tener reacciones adversas al fármaco. El protocolo de desensibilización para
Nadia Karina Aguilar Hinojosa, Evelyn Itzamara Figueroa Saavedra   +1 more
doaj   +1 more source

Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions [PDF]

, 2017
Non-transfusion-dependent thalassaemias (NTDT) encompass a spectrum of anaemias rarely requiring blood transfusions. Increased iron absorption, driven by hepcidin suppression secondary to erythron expansion, initially causes intrahepatic iron overload ...
Bansal, Brissot, Cabantchik, Dussiot, Esposito, Fucharoen, Fucharoen, Galanello, Galanello, Gardenghi, Harteveld, Kautz, Lal, Lal, Loreal, Musallam, Musallam, Musallam, Musallam, O'Donnell, Origa, Pakbaz, Pasricha, Pippard, Pootrakul, Porter, Premawardhena, Rees, Ricchi, St Pierre, Taher, Taher, Taher, Taher, Taher, Taher, Tanno, Tanno, Vichinsky, Vichinsky, Walter, Weatherall, Worwood   +42 more
core   +1 more source

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients [PDF]

Pharmaceutics, 2021
Background: Deferasirox (DFX) is commonly used to reduce the chronic iron overload (IO) in pediatric patients. However, the drug is characterized by a large pharmacokinetic variability and approximately 10% of patients may discontinue the treatment due to toxicities.
Laura Galeotti, Francesco Ceccherini, Carmen Fucile, Valeria Marini, Antonello Di Paolo, Natalia Maximova, Francesca Mattioli   +6 more
openaire   +6 more sources

Deferasirox, an oral chelator in the treatment of iron overload

Italian Journal of Medicine, 2013
BACKGROUND Deferasirox is a once-daily oral iron chelator developed for treating iron overload complicating long-term transfusion therapy in patients with diseases such as beta-thalassemia and myelodysplastic syndromes. Iron overload can damage the liver,
I. Portioli
doaj   +1 more source

Deferasirox-induced cytogenetic responses

Environmental Toxicology and Pharmacology, 2015
Deferasirox (commercially formulated as Exjade(®)) is one of the effective iron chelators used in treatment of iron overload diseases. In this study the effect of this substance for chromosome aberration, sister chromatid exchange and mitotic index was studied by in vitro (by using human peripheral lymphocytes) and in vivo (by using rat) analysis ...
Mehmet Arslan, Hasan Basri Ila
openaire   +4 more sources

Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Ferroptosis, an iron‐dependent form of regulated cell death, is a major cell death mode in myocardial ischemia reperfusion (I/R) injury, along with mitochondrial permeability transition‐driven necrosis, which is inhibited by cyclosporine A ...
Kosei Ishimaru, Masataka Ikeda, Hiroko Deguchi Miyamoto, Shun Furusawa, Ko Abe, Masatsugu Watanabe, Takuya Kanamura, Satoshi Fujita, Ryohei Nishimura, Takayuki Toyohara, Shouji Matsushima, Tomoko Koumura, Ken‐ichi Yamada, Hirotaka Imai, Hiroyuki Tsutsui, Tomomi Ide   +15 more
doaj   +1 more source

Perbedaan Kadar Thyroid Stimulating Hormone dan Free Thyroxine pada Pasien Talasemia Β-Mayor dengan Kelasi Besi Deferasirox dan Deferiprone

Sari Pediatri, 2018
Latar belakang. Talasemia β Mayor merupakan kelainan herediter yang disebabkan gangguan produksi rantai globin. Transfusi rutin menyebabkan kelebihan besi yang tertimbun dalam jaringan sehingga menyebabkan kardiomiopati, gangguan liver, dan komplikasi ...
Aries - Krisbiyantoro, Harsono Salimo, Annang Giri Moelyo   +2 more
doaj   +1 more source

Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin [PDF]

, 2017
Cardiosiderosis is a leading cause of mortality in transfusion-dependent thalassemias. Plasma non-transferrin-bound iron and its redox-active component, labile plasma iron, are key sources of iron loading in cardiosiderosis.
Evans, P, Garbowski, MW, Hider, R, Porter, JB, Vlachodimitropoulou, E   +4 more
core   +1 more source